123 related articles for article (PubMed ID: 18365199)
1. cis-3, 4', 5-Trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion.
Durrant D; Corwin F; Simoni D; Zhao M; Rudek MA; Salloum FN; Kukreja RC; Fatouros PP; Lee RM
Cancer Chemother Pharmacol; 2009 Jan; 63(2):191-200. PubMed ID: 18365199
[TBL] [Abstract][Full Text] [Related]
2. Stilbene derivatives that are colchicine-site microtubule inhibitors have antileukemic activity and minimal systemic toxicity.
Cao TM; Durrant D; Tripathi A; Liu J; Tsai S; Kellogg GE; Simoni D; Lee RM
Am J Hematol; 2008 May; 83(5):390-7. PubMed ID: 18175355
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of cell death induced by cis-3, 4', 5-trimethoxy-3'-aminostilbene in ovarian cancer.
Durrant D; Richards JE; Walker WT; Baker KA; Simoni D; Lee RM
Gynecol Oncol; 2008 Jul; 110(1):110-7. PubMed ID: 18433847
[TBL] [Abstract][Full Text] [Related]
4. Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'-aminostilbene for optimization and use in cancer therapy.
Durrant DE; Richards J; Tripathi A; Kellogg GE; Marchetti P; Eleopra M; Grisolia G; Simoni D; Lee RM
Invest New Drugs; 2009 Feb; 27(1):41-52. PubMed ID: 18516499
[TBL] [Abstract][Full Text] [Related]
5. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
6. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation.
Rupertus K; Dahlem C; Menger MD; Schilling MK; Kollmar O
Ann Surg Oncol; 2009 Sep; 16(9):2629-37. PubMed ID: 19551445
[TBL] [Abstract][Full Text] [Related]
8. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
9. ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.
Luo Y; Hradil VP; Frost DJ; Rosenberg SH; Gordon GB; Morgan SJ; Gagne GD; Cox BF; Tahir SK; Fox GB
Anticancer Drugs; 2009 Jul; 20(6):483-92. PubMed ID: 19398903
[TBL] [Abstract][Full Text] [Related]
10. Alterations in vascular architecture and permeability following OXi4503 treatment.
Chan LS; Malcontenti-Wilson C; Muralidharan V; Christophi C
Anticancer Drugs; 2008 Jan; 19(1):17-22. PubMed ID: 18043126
[TBL] [Abstract][Full Text] [Related]
11. [Adenovirus mediated angiostatin gene therapy for ovarian cancer: experiment with nude mice].
Jia CR; Yang SY; Han SY; Sun L
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(31):2204-8. PubMed ID: 19080673
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1.
van Herpen CM; Bussink J; van der Kogel AJ; Peeters WJ; van der Voort R; van Schijndel A; de Wilde PC; Adema GJ; de Mulder PH
Anticancer Res; 2005; 25(2A):1015-21. PubMed ID: 15868941
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect.
Szentirmai O; Baker CH; Lin N; Szucs S; Takahashi M; Kiryu S; Kung AL; Mulligan RC; Carter BS
Neurosurgery; 2006 Feb; 58(2):365-72; discussion 365-72. PubMed ID: 16462491
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitive effects of mifepristone on growth of breast cancer: experiment with animal model].
Tian XS; Zhou WH; Wu GJ; Sun JZ; Cong MH
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):559-63. PubMed ID: 18649774
[TBL] [Abstract][Full Text] [Related]
15. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
16. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line.
Schuuring J; Bussink J; Bernsen HJ; Peeters W; van Der Kogel AJ
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):529-34. PubMed ID: 15667976
[TBL] [Abstract][Full Text] [Related]
17. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors.
Burrows FJ; Watanabe Y; Thorpe PE
Cancer Res; 1992 Nov; 52(21):5954-62. PubMed ID: 1394221
[TBL] [Abstract][Full Text] [Related]
18. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice.
Estella-Hermoso de Mendoza A; Campanero MA; de la Iglesia-Vicente J; Gajate C; Mollinedo F; Blanco-Prieto MJ
Clin Cancer Res; 2009 Feb; 15(3):858-64. PubMed ID: 19188156
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
20. Efficient inhibition of ovarian cancer growth and prolonged survival by transfection with a novel pro-apoptotic gene, hPNAS-4, in a mouse model. In vivo and in vitro results.
Yang F; Li Z; Deng H; Yang H; Yan F; Qian Z; Chen L; Wei Y; Zhao X
Oncology; 2008; 75(3-4):137-44. PubMed ID: 18824876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
